SERPINE1 and melanoma: To address these unmet medical needs, especially in Japanese patients with advanced melanoma, a single-arm, phase 2 clinical trial to evaluate the efficacy and safety of nivolumab plus a PAI-1 inhibitor, TM5614, in Japanese patients with metastatic melanoma is ongoing (jRCT2021210029) [93].